The status of platinum anticancer drugs in the clinic and in clinical trials
about
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profileAdvances in drug delivery system for platinum agents based combination therapyRedox activation of metal-based prodrugs as a strategy for drug deliveryStructural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivativesThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsCarbon nanotubes as cancer therapeutic carriers and mediatorsDeterminants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijackingPrediction of cancer drugs by chemical-chemical interactionsMethylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer DrugThe elements of life and medicinesColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerDisturbance of DNA conformation by the binding of testosterone-based platinum drugs via groove-face and intercalative interactions: a molecular dynamics simulation study.Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopyAmide coupling reaction for the synthesis of bispyridine-based ligands and their complexation to platinum as dinuclear anticancer agentsAn unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency.Targeting DNA Mismatches with Rhodium Metalloinsertors.A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties.Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion.Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug deliveryEncapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage.Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatinConjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.Using Drosophila melanogaster to identify chemotherapy toxicity genes.Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.Nanocarriers for delivery of platinum anticancer drugs.Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.Understanding and improving platinum anticancer drugs--phenanthriplatinThe interaction of platinum-based drugs with native biologically relevant proteins.Trial Watch: Peptide-based anticancer vaccines.The ex vivo neurotoxic, myotoxic and cardiotoxic activity of cucurbituril-based macrocyclic drug delivery vehicles.Synthesis, characterization, interaction with DNA and cytotoxicity of Pd(II) and Pt(II) complexes containing pyridine carboxylic acid ligands.A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapyLobaplatin inhibits growth of gastric cancer cells by inducing apoptosisSynthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexesPolysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy
P2860
Q24625759-B56032D2-40B9-4949-B28F-1601C1BDDB9EQ26771390-55E1E023-285C-4253-ABA6-36B55CC80C1AQ27025736-6140FA53-7FFB-4E33-8058-2F08346221D9Q27678705-E71FEAD5-715D-4669-BB66-BC4AE4892E4FQ27702884-80027D28-1BA8-453C-83FA-82EBFC9A8FCEQ28066801-D05B89EF-D11F-4679-A580-37E39633459AQ28074309-3C11FE8A-8D0E-408F-82FE-1339A28CA752Q28534972-6E8F9890-063A-4D4B-BD7D-B469768F2DC1Q28539449-E16BE2D7-87EF-46D9-8F44-CB20522125B7Q28540634-9D2F76C6-7301-4B9E-9ABB-9C84CF6D6C69Q28547627-ED0B871C-37FF-4BD9-9DAD-0661A59275D3Q28649323-25BE502A-BAD1-490A-AE2B-F3C53D5E6E3BQ30238915-FE56D3A9-0CB1-4197-84E1-1B3FD4387D0BQ30538107-C7F32660-659B-4A93-80AD-67F62C9427D6Q30682911-E5B78C37-8E49-41AA-B2DD-C7FEC33BA513Q30828730-C549F660-9ED3-4161-9DDB-0A1FA363F472Q30855124-29869998-E1D8-49EB-985C-F5D5E0D8CE9DQ31136996-8603811D-769D-4F88-B320-0FC2D7AAA284Q33415717-98C99A1B-2F56-4FC0-A0EB-D435407168ABQ33615268-95E323F5-F108-45B7-AA21-D2E6C0EC5F04Q33696556-5F4C515E-C6AD-4E4E-B649-C9C0CE363240Q33716280-F1E36FAD-10ED-41E9-ADEC-AACAAC0ECE93Q33798812-DB2213FA-532B-4713-B29B-F88838744E28Q33825880-9B5F3C1F-7F04-44C7-BF34-8971581CFC6CQ33917124-7291A8DC-917A-4400-A824-6B4EF5BC5AE8Q34028040-A12D222C-3C8E-4A84-A17F-D7A4ECDAA5BCQ34060461-5CC4D6AC-4ACF-4A0E-9DEC-A10112223CB5Q34242959-2417410E-E276-49ED-94C9-186413BF754DQ34331245-367638E3-C55B-4176-A058-4243F1DBF4ECQ34338695-A576D01E-3608-413B-BC58-5E976D5EAE6CQ34377003-2BD8BB2B-6E9F-47CE-8D01-18F4601D48B1Q34396623-F597F60F-6873-4D49-8677-3270A263E02CQ34439746-3B9BD082-3436-42BD-8C0A-C1593D3B561EQ34483345-EF0E0A6A-E1AF-46DE-85A8-9CF466F2B25EQ34523282-A7FDB35A-FBB0-4749-9062-EEA624A0A544Q34555057-6BBB0F2C-FA61-4EC6-90A4-04E8EC51B41DQ34583261-01EFE785-9325-427A-809B-B23BCBB8BBA5Q34696650-95FACBD6-B710-480C-9FBB-E83DC2CF645FQ34731239-E0DBB846-CCBD-471E-A223-C8CD36DD9861Q34791190-E6E8E02C-B2EE-4391-B11C-A630E9C65A19
P2860
The status of platinum anticancer drugs in the clinic and in clinical trials
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The status of platinum anticancer drugs in the clinic and in clinical trials
@ast
The status of platinum anticancer drugs in the clinic and in clinical trials
@en
The status of platinum anticancer drugs in the clinic and in clinical trials
@nl
type
label
The status of platinum anticancer drugs in the clinic and in clinical trials
@ast
The status of platinum anticancer drugs in the clinic and in clinical trials
@en
The status of platinum anticancer drugs in the clinic and in clinical trials
@nl
prefLabel
The status of platinum anticancer drugs in the clinic and in clinical trials
@ast
The status of platinum anticancer drugs in the clinic and in clinical trials
@en
The status of platinum anticancer drugs in the clinic and in clinical trials
@nl
P2093
P2860
P3181
P356
P1433
P1476
The status of platinum anticancer drugs in the clinic and in clinical trials
@en
P2093
Gemma E Craig
Rabbab Oun
Shonagh Walker
P2860
P304
P3181
P356
10.1039/C0DT00292E
P407
P577
2010-09-21T00:00:00Z